LY2857785 is a potent inhibitor of poly (ADP-ribose) polymerase (PARP), primarily investigated for its potential therapeutic applications in oncology, particularly in cancers associated with BRCA gene mutations. BRCA genes are involved in DNA repair, and LY2857785 works by inhibiting the PARP enzyme, which plays a key role in this process. In cells with BRCA mutations, PARP inhibition prevents the repair of damaged DNA, leading to cancer cell death. Research has focused on its efficacy in treating BRCA-mutated cancers, with preclinical studies showing promising results in reducing tumor growth and enhancing the effectiveness of other treatments like chemotherapy or radiation when used in combination. Its application is being explored in clinical trials to evaluate safety, dosage, and overall impact on patient outcomes. Additionally, it may hold potential in personalized medicine, where treatment is tailored based on the genetic profile of the cancer.